WT1 and cancer: A TCR-mimic antibody targeting a Wilms tumor 1 (WT1) peptide in the context of HLA-A2 has demonstrated efficacy in preclinical models (36); however, the ability to specifically target MANAs is critical to make these strategies applicable to a wide range of cancer patients.